Should I buy or sell Lisata Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LSTA shares. View LSTA analyst ratings or view top-rated stocks .

What is Lisata Therapeutics' stock price target for 2024?

1 analysts have issued twelve-month price objectives for Lisata Therapeutics' shares. Their LSTA share price targets range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts .

How have LSTA shares performed in 2024?

Lisata Therapeutics' stock was trading at $2.73 on January 1st, 2024. Since then, LSTA stock has decreased by 1.1% and is now trading at $2.70. View the best growth stocks for 2024 here .

Are investors shorting Lisata Therapeutics?

Lisata Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,800 shares, an increase of 69.7% from the March 15th total of 9,900 shares. Based on an average daily volume of 13,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.3% of the company's shares are sold short. View Lisata Therapeutics' Short Interest .

When is Lisata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LSTA earnings forecast .

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.20.

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free LSTA Stock Alerts

$2.70

-0.15 (-5.26%)

(As of 05:21 PM ET)

Compare

Today's Range: $2.67
▼
$2.87
50-Day Range: $2.66
▼
$3.35
52-Week Range: $1.95
▼
$4.53

Volume: 1,975 shs
Average Volume: 13,290 shs
Market Capitalization: $22.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Lisata Therapeutics alerts:

Lisata Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 455.6% Upside
$15.00 Price Target
Short Interest: Healthy
0.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.08) to ($2.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

Medical Sector

493rd out of 911 stocks

Pharmaceutical Preparations Industry

218th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.25% of the float of Lisata Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Lisata Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lisata Therapeutics has recently increased by 69.70%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lisata Therapeutics does not currently pay a dividend.
Dividend Growth
Lisata Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LSTA.

1.4

News and Social Media Coverage

News Sentiment
Lisata Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Lisata Therapeutics this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.60% of the stock of Lisata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($3.08) to ($2.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lisata Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lisata Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lisata Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

LSTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LSTA Stock News Headlines

April 19, 2024 | americanbankingnews.com

Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 2.5%

April 11, 2024 | finanznachrichten.de

Lisata Therapeutics, Inc.: Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 9, 2024 | markets.businessinsider.com

Lisata Receives FDA Orphan Drug Designation For LSTA1 To Treat Osteosarcoma

April 9, 2024 | globenewswire.com

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

April 3, 2024 | globenewswire.com

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

March 21, 2024 | msn.com

Lisata gets FDA rare pediatric disease status for lead drug

March 21, 2024 | markets.businessinsider.com

Lisata's LSTA1 Gets Rare Pediatric Disease Designation From FDA For Osteosarcoma

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | globenewswire.com

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

March 15, 2024 | finance.yahoo.com

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

March 4, 2024 | financialpost.com

Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ

March 2, 2024 | seekingalpha.com

Lisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript

March 1, 2024 | finanznachrichten.de

Lisata Therapeutics, Inc.: Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 1, 2024 | finance.yahoo.com

Q4 2023 Lisata Therapeutics Inc Earnings Call

February 29, 2024 | benzinga.com

Recap: Lisata Therapeutics Q4 Earnings

February 29, 2024 | globenewswire.com

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

February 28, 2024 | benzinga.com

Lisata Therapeutics's Earnings Outlook

February 22, 2024 | globenewswire.com

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

February 20, 2024 | finance.yahoo.com

Lisata Therapeutics to Present at BIO CEO & Investor Conference

February 20, 2024 | globenewswire.com

Lisata Therapeutics to Present at BIO CEO & Investor Conference

January 18, 2024 | msn.com

Lisata Therapeutics treats first patient in Phase IIa trial of LSTA1 drug

January 17, 2024 | finance.yahoo.com

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

January 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lisata Therapeutics on Strong Clinical Prospects for LSTA1

January 4, 2024 | finance.yahoo.com

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

December 13, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Lisata Therapeutics (LSTA) and Oric Pharmaceuticals (ORIC)

See More Headlines

Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LSTA
CUSIP: N/A
CIK: 320017
Web: www.caladrius.com
Phone: (908) 842-0100
Fax: 646-514-7787
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +457.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.06%
Return on Assets: -34.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.18
Quick Ratio: 8.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.88 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 8,310,000
Free Float: 6,513,000
Market Cap: $22.35 million
Optionable: Not Optionable
Beta: 1.04

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. David J. Mazzo B.A. (Hons) (Age 67)
B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director
Comp: $1.16M
Dr. Kristen K. Buck M.D. (Age 49)
Executive VP of R&D and Chief Medical Officer
Comp: $938.42k
Mr. James Nisco
VP of Finance & Treasury
Mr. Tariq Imam
Vice President of Business Development & Operations and Corporate Counsel
Mr. Gregory S. Berkin
Chief Information Officer
Mr. John D. Menditto
Vice President of Investor Relations & Corporate Communications
Ms. Gail Holler (Age 65)
Vice President of Human Resources
Dr. William K. Sietsema Ph.D. (Age 68)
Vice President of Global Regulatory Affairs
Comp: $350.55k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LSTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lisata Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LSTA shares.
View LSTA analyst ratings or view top-rated stocks.
What is Lisata Therapeutics' stock price target for 2024?: 1 analysts have issued twelve-month price objectives for Lisata Therapeutics' shares. Their LSTA share price targets range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price.
View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts.
How have LSTA shares performed in 2024?: Lisata Therapeutics' stock was trading at $2.73 on January 1st, 2024. Since then, LSTA stock has decreased by 1.1% and is now trading at $2.70.
View the best growth stocks for 2024 here.
Are investors shorting Lisata Therapeutics?: Lisata Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,800 shares, an increase of 69.7% from the March 15th total of 9,900 shares. Based on an average daily volume of 13,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.3% of the company's shares are sold short.
View Lisata Therapeutics' Short Interest.

When is Lisata Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LSTA earnings forecast.
How were Lisata Therapeutics' earnings last quarter?: Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.20.
How do I buy shares of Lisata Therapeutics?: Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LSTA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial